HTB homepage • Conference reports • Articles by subject • Subscribe May 2000 Contents Treatment alerts EMEA public statement on Viramune (nevirapine): severe and life-threatening cutaneous and hepatic reactions Conference reports Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA Clinical studies of indinavir/ritonavir as salvage therapy Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations? First International Workshop in Clinical Pharmacology in HIV Therapy, 30-31 March 2000, Noordwijk, Netherlands TDM: standardisation and quality control TDM in clinical practice ATHENA – Early results from first randomised study of clinical benefits of TDM TDM for individualising dosing – practicality and efficacy for PIs and RTIs TDM and adherence Drug interactions: amprenavir, saquinavir, ABT-378/r (lopinavir/r), indinavir, efavirenz, ritonavir L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation Antiretrovirals ABT-378/r (lopinavir) now available on named patient basis in UK Enteric coated ddI available on named patient basis in UK Nelfinavir potency concerns Treatment strategies GM-CSF beneficial for patients with advanced HIV disease Paediatric care Liquid formulation of efavirenz available for children in the uk on named patient basis Most reconstituted CD4 cells naive after HAART in children with HIV Side effects Decreased bone mineral density and HIV protease inhibitors Virology A view from the lab: interview with Professor Clive Loveday PDFs Volume 1 Number 2 May 2000 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
